Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG ‐ MM5 Trial
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70061 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Tim Richardson und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin A, Immunoglobulin G. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celgene, Chugai Pharmaceutical, Johnson and Johnson.
Abstract (Originalsprache)
Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to therapy. Using serum samples of 360 evaluable patients from the prospective GMMG‐MM5 trial (EudraCT‐No. 2010–019173‐16) we assessed the normalization of the kappa/lambda ratio with the Hevylite Assay (HLCr) at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow‐up within two years after the end of consolidation. We observed a steady increase in the proportion of patients with normalized HLCr over the course of therapyAchieving HLCr normalization any time until the end of consolidation was associated with a trend towards a prolonged progression‐free survival (PFS; hazard ratio (HR) = 0.75, 95% confidence interval (95% CI) = 0.56–1.01, p = 0.06) but not overall survival (OS; HR = 0.94, 95% CI = 0.69–1.26, p = 0.66) in multivariable time‐dependent Cox regression analyses. Using a landmark analysis from the end of consolidation there was again a marginally statistically significant effect of HLCr normalization by the end of consolidation on PFS using a multivariable Cox model on the subset of the two study arms with continuous lenalidomide maintenance (HR 0.61, 95% CI 0.37–1.02, p = 0.06). No such effect was observed in study arms in which maintenance was only applied to patients not in CR at the end of consolidation. In conclusion, our analysis of the Hevylite Assay in patients with IgG or IgA myeloma from the GMMG‐MM5 study did not find evidence to support the general use of HLCr normalization as a response parameter for predicting PFS or OS. However, the differential effects of HLCr normalization depending on the way in which treatment was adapted to response may be of interest for future study designs on response‐adapted therapy. Trial Registration: ISRCTN05622749.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
- Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Internal Medicine III, Chemnitz, Germany.
- Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
- Department of Hematology, University Clinic Essen, Essen, Germany.
ORCID-Profile: Tim Richardson, Elias Mai, Ekaterina Menis, Axel Benner, Kaya Miah, Mathias Hänel, Christian S Michel, Hans Walter Lindemann, Peter Brossart, Hans Salwender, Hartmut Goldschmidt, Christof Scheid
Förderung
- Celgene
- Chugai Pharmaceutical
- Johnson and Johnson
- Binding Site GmbH is part of Thermo Fisher Scientific
Zitieren
APA
Richardson, T., Mai, E., Menis, E., Benner, A., Tichy, D., Miah, K., Hänel, M., Besemer, B., Boquoi, A., Blau, I. W., Michel, C. S., Lindemann, H. W., Janjetovic, S., Brossart, P., Bernhard, H., Reimer, P., Salwender, H., Hose, D., Seckinger, A., …, & German‐Speaking Myeloma Multicenter Group (GMMG) HD5 Investigators (2026). Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG ‐ MM5 Trial. European Journal of Haematology. https://doi.org/10.1111/ejh.70061
Vancouver
Richardson T, Mai E, Menis E, Benner A, Tichy D, Miah K, et al. Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG ‐ MM5 Trial. European Journal of Haematology. 2026. doi:10.1111/ejh.70061
BibTeX
@article{Richardson2026,
author = {Richardson, Tim and Mai, Elias and Menis, Ekaterina and Benner, Axel and Tichy, Diana and Miah, Kaya and Hänel, Mathias and Besemer, Britta and Boquoi, Amelie and Blau, Igor Wolfgang and Michel, Christian S and Lindemann, Hans Walter and Janjetovic, Snjezana and Brossart, Peter and Bernhard, Helga and Reimer, Peter and Salwender, Hans and Hose, Dirk and Seckinger, Anja and Raab, Marc and Goldschmidt, Hartmut and Scheid, Christof and German‐Speaking Myeloma Multicenter Group (GMMG) HD5 Investigators, German‐Speaking Myeloma Multicenter Group (GMMG) HD5 Investigators},
title = {Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG ‐ MM5 Trial},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70061}
}
EUVIMED